Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled the release of its full year 2024 financial results for March 19, 2025. The company will conduct a live webcast at 8:30 a.m. Eastern Time to present the financial results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.
Liquidia (NASDAQ: LQDA), un'azienda biofarmaceutica focalizzata sulle terapie per malattie cardiopolmonari rare, ha programmato la pubblicazione dei suoi risultati finanziari per l'intero anno 2024 per il 19 marzo 2025. L'azienda condurrà una diretta web alle 8:30 ora orientale per presentare i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori possono accedere alla diretta attraverso il sito web di Liquidia, dove rimarrà archiviata per un anno.
Liquidia (NASDAQ: LQDA), una empresa biofarmacéutica centrada en terapias para enfermedades cardiopulmonares raras, ha programado la publicación de sus resultados financieros del año completo 2024 para el 19 de marzo de 2025. La empresa realizará una transmisión en vivo a las 8:30 a.m. hora del Este para presentar los resultados financieros y proporcionar una actualización corporativa. Los inversores pueden acceder a la transmisión a través del sitio web de Liquidia, donde permanecerá archivada durante un año.
리퀴디아 (NASDAQ: LQDA)는 희귀 심폐 질환 치료를 전문으로 하는 생명공학 회사로, 2024 회계연도 전체 재무 결과 발표를 2025년 3월 19일로 예정했습니다. 회사는 동부 표준시 기준 오전 8시 30분에 재무 결과를 발표하고 기업 업데이트를 제공하기 위해 라이브 웹캐스트를 진행할 것입니다. 투자자들은 리퀴디아의 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 이 웹캐스트는 1년 동안 아카이브로 남아있을 것입니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique spécialisée dans les thérapies pour les maladies cardiopulmonaires rares, a prévu de publier ses résultats financiers pour l'année complète 2024 le 19 mars 2025. L'entreprise organisera un webinaire en direct à 8h30 heure de l'Est pour présenter les résultats financiers et fournir une mise à jour de l'entreprise. Les investisseurs peuvent accéder au webinaire via le site web de Liquidia, où il restera archivé pendant un an.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene kardiopulmonale Erkrankungen konzentriert, hat die Veröffentlichung seiner Jahresfinanzberichte 2024 für den 19. März 2025 geplant. Das Unternehmen wird um 8:30 Uhr Eastern Time ein Live-Webcast durchführen, um die finanziellen Ergebnisse zu präsentieren und ein Unternehmensupdate zu geben. Investoren können auf den Webcast über die Website von Liquidia zugreifen, wo er ein Jahr lang archiviert bleibt.
- None.
- None.
MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) release its full year 2024 financial results?
What time is Liquidia's (LQDA) earnings webcast scheduled for March 19, 2025?
Where can investors access Liquidia's (LQDA) March 2025 earnings webcast?
How long will Liquidia's (LQDA) March 2025 earnings webcast be available for replay?
